Table 3 Average changes in parameters of primary and secondary outcomes during treatment based on a mixed-effects model analysis.

From: Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study

Parameter (unit)

Average change (95% CI)

P-value*

Sitagliptin

Control

Difference

Interaction

Anthropometry

Body weight (kg)

0.06 (− 0.33; 0.45)

− 0.37 (− 0.78; 0.05)

0.14

0.46

BMI (kg/m2)

− 0.01 (− 0.17; 0.15)

− 0.18 (− 0.35; − 0.01)

0.14

0.59

Glucose metabolism

FPG (mg/dL)

− 27.2 (− 37.7; − 16.8)

0.50 (− 10.3; 11.3)

< 10−3

0.81

GA (%)

− 2.39 (− 2.97; − 1.81)

− 0.93 (− 1.53; − 0.32)

< 10−3

0.65

HbA1c (%)

− 0.61 (− 0.77; − 0.45)

− 0.29 (− 0.46; − 0.12)

< 0.01

0.45

Insulin (μU/mL)a

− 0.98 (− 2.07; 0.11)

0.68 (− 0.44; 1.80)

0.04

0.49

Proinsulin (pmol/L)a

− 4.33 (− 7.84; − 0.82)

− 2.20 (− 5.79; 1.39)

0.43

0.10

Renal function

Cr (mg/dL)

0.04 (0.03; 0.05)

− 0.01 (− 0.02; 0.01)

< 10−4

0.12

CysC (mg/L)

0.05 (0.03; 0.07)

0.00 (− 0.02; 0.02)

< 0.01

0.23

Cr-based eGFR

− 3.13 (− 4.30; − 1.96)

0.66 (− 0.55; 1.88)

< 10−4

0.10

CysC-based eGFR

− 3.89 (− 5.30; − 2.48)

0.17 (− 1.29; 1.63)

< 10−4

0.34

uACR (mg/g Cr)

− 19.6 (− 67.9; 28.6)

21.1 (− 29.1; 71.3)

0.27

0.39

ln[uACR]

− 0.21 (− 0.35; − 0.06)

0.06 (− 0.09; 0.21)

0.01

0.95

  1. *‘Difference’ indicates the average change in parameters of primary and secondary outcomes caused by a specific treatment. ‘Interaction’ occurs when the length of treatment affected the average change in a selected parameter. aFollow-up measurements were performed at 3 and 6 months. BMI body mass index, Cr creatinine, CysC Cystatin C, eGFR estimated glomerular filtration rate (mL/min/1.73 m2), FPG fasting plasma glucose, GA glycated albumin, ln[uACR] logarithmic urinary albumin-creatinine ratio, uACR urinary albumin-creatinine ratio.
Back to article page